基于随机森林和LASSO回归算法的结直肠癌相关的长非编码RNA的查和验证
Yujia Zhao1, Qian Li1,2, Xintong Cui1
1Department of Health Statistics, School of Public Health, Shenyang Medical College, 146 Huanghe North Street, Shenyang, 110034, China.
Discover oncology
|July 1, 2025
概括
这项研究确定了与结直肠癌 (CRC) 相关的五种长非编码RNA (lncRNA). 其中四种,NCAL1,HMGA1P4,EPIST和MT1JP,显示出作为CRC检测和诊断的新生物标志物的潜力.
科学领域:
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
- 癌症研究 癌症研究
背景情况:
- 结肠直肠癌 (CRC) 是一个主要的全球健康负担,死亡率高.
- 长非编码RNAs (lncRNAs) 越来越多地被认为是它们在癌症发展中的调节作用.
- 识别新的生物标志物对于早期检测和有效治疗CRC至关重要.
研究的目的:
- 使用生物信息学和机器学习识别和验证结直肠癌 (CRC) 的新型长非编码RNA (lncRNA) 生物标志物.
- 探索lncRNAs作为CRC的诊断和预后指标的潜力.
主要方法:
- 利用了来自GEO数据库的结直肠癌和正常组织的RNA-seq数据.
- 采用随机森林 (RF) 和 LASSO 回归算法来选差异表达的 lncRNA (DE lncRNA).
- 预测的lncRNA-miRNA-mRNA调节网络和通过qRT-PCR验证的lncRNA表达.
主要成果:
- 选了3028个与CRC相关的lncRNA,确定了55个DE lncRNA,随后确定了五个关键的lncRNA:NCAL1,CRNDE,HMGA1P4,EPIST和MT1JP.
- NCAL1,CRNDE和HMGA1P4显示上调,而EPIST和MT1JP在CRC组织中显示下调.
- 实验验证证证实了CRC组织中四个关键lncRNAs (NCAL1,HMGA1P4,EPIST,MT1JP) 的显著差异表达 (p < 0.001).
结论:
- 确定了五种 lncRNAs (NCAL1,CRNDE,HMGA1P4,EPIST,MT1JP),可能与结直肠癌相关.
- NCAL1,HMGA1P4,EPIST和MT1JP显示为结直肠癌的候选生物标志物具有前景.
相关概念视频
lncRNA - Long Non-coding RNAs
9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458


